Ultragenyx stock jumps after FDA approves Fayuvi for Sanfilippo A
FDA approval of Ultragenyx Pharmaceutical’s Fayuvi for children with Sanfilippo syndrome type A sent the shares up about 12% to $14.44 late Thursday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.